Volume 62, Issue 6 pp. 841-846
Radiation Oncology—Original Article

Hyperbaric oxygen treatment for the management of radiation-induced xerostomia

Susannah Sherlock

Corresponding Author

Susannah Sherlock

Hyperbaric Medicine Unit, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

Anaesthesia and Perioperative Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia

Correspondence

Dr Susannah Sherlock, Royal Brisbane and Women's Hospital, Butterfield St, Herston, Qld 4029, Australia.

Email: [email protected]

Search for more papers by this author
Mandy Way

Mandy Way

QIMR Berghofer Institute, Biostatistics, Brisbane, Queensland, Australia

Search for more papers by this author
Alexis Tabah

Alexis Tabah

Hyperbaric Medicine Unit, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia

Intensive Care Unit, Redcliffe Hospital, Redcliffe, Queensland, Australia

Search for more papers by this author
First published: 16 August 2018
Citations: 10
S Sherlock BSc, MBBS, FANZCA, Dip DHM (SPUMS), Adv Dip DHM (ANZCA); M Way BSc (Hons), Dip Ed, M Biostat; A Tabah MD, FCICM.
Conflict of interest: None.

Abstract

Introduction

Hyperbaric oxygen therapy (HBOT) is widely used for the treatment of the late effects of radiation therapy. We report a prospective observational cohort study of 51 patients designed to examine the effectiveness of hyperbaric oxygen treatment (HBOT) for xerostomia following radiotherapy.

Methods

Objective (saliva volume) and subjective (quality of life scoring and visual analogue scale (VAS) of discomfort) measurements associated with xerostomia were compared prior to commencement of HBOT, after 30 sessions (over 6 weeks) of HBOT at 243 kPa for 90 minutes daily for five days per week and at 6-week review (12 weeks from commencement).

Results

One hundred and one courses of treatment in 99 patients were examined. For 53 (53%) courses in 51 patients, data were recorded before and after HBOT and so could be included in the analysis. Thirty-four (34%) of these patients had complete data for all three time points. The unit of study was per treatment course, not per person. There were no major complications to HBOT. There was a statistically significant difference in saliva volume following HBOT (P = 0.016). The mean saliva volume increase was 0.9 mL over a 5-min collection period (95% CI 0.2–1.5). There was also a statistically significant improvement in discomfort after HBOT (P < 0.001) and QOL (P < 0.001). The mean visual analogue scale for discomfort (VAS on a 0–10 scale) score decreased by 1.4 units (95% CI 0.7–2.1), whilst the mean QOL score was 10 points lower after treatment (95% CI 5.9–14.4).

Conclusion

Hyperbaric oxygen therapy may be a safe and effective treatment for symptoms of xerostomia after radiation therapy and should be considered when available.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.